Hernández-Bastida A

Language: Spanish
References: 34
Page: 125-136
PDF size: 648.02 Kb.

ABSTRACT

Background: Obesity has highly prevalence in Mexico and represents seriously implications over health, so new treatments have awakened a great interest.
Objectives: To characterize the efficacy and safety of the combination of phentermine plus topiramate in overweight, obesity type I and obesity type II patients and evaluate the impact of the combination over risk and safety factors.
Material and method: A comparative, randomized, double-blind, prospective, parallel groups trial was done including male and female patients from 18 to 60 years old with overweight or obesity diagnosis. Patients were allocated in one of the following treatment groups: Phentermine (7.5 mg) plus topiramate (50 mg); phentermine (15 mg) plus topiramate (100 mg); phentermine (15 mg) plus placebo and phentermine (30 mg) plus placebo daily during 12 weeks. The dietetic regimen was performed in individual way in agreement with the alimentary preferences of each patient by the nutriologist, for assure diet compliance.
Results: The phentermine (15 mg) plus topiramate (100 mg) showed the greatest reductions in weight, BMI, waist and hip circumference, also in the metabolic variables (lipids and glucose) the reductions were the most significant. Phentermine 30 mg group showed also significant reductions in body weight, BMI, waist and hip circumference and in the metabolic variables (lipids and glucose), but these reductions were lowest than phentermine plus topiramate group. The most frequent side events were paresthesias and dry mouth, these effects decreased in frequency and intensity during the study.
Conclusions: Phentermine plus topiramate demonstrated to be safe and efficient over weight and metabolic variables and this combination could be a new alternative treatment for overweight and obesity.

REFERENCES

1. Norma Oficial Mexicana NOM-174-SSA1-1998 para el manejo integral de la obesidad. Publicada en el Diario Oficial de la Federación. México: Secretaría de Salud, 2001.

2. Arroyo P, Loria A, Fernández V, et al. Prevalence of preobesity and obesity in urban adult Mexicans in comparison with other large surveys. Obes Res 2000;8:179-185.

3. Williamson DF, Kahn HS, Remington PL, et al. The 10 year incidence of overweight and major weight gain in US adults. Arch Intern Med 1990;150:665-672.

4. Williamson DF, Kahn HS, Byers ST. The 10-year incidence of obesity and major weight gain in black and white US women aged 30-55 years. Am J Clin Nutr 1991;5:1515-1518.

5. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-211.

6. Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.

7. Sánchez-Reyes L, Berber A y Fanghänel G. Incidencia de obesidad en una población mexicana. Rev Endocrinol Nutr 2001;9:60-66.

8. La salud en los adultos. Encuesta Nacional de Salud (ENSA) 2000. Instituto Nacional de Salud Pública. Secretaría de Salud, 2003.

9. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin 2003;32:134-140.

10. Glazer G. Long-term pharmacotherapy of obesity 2000. Ach Intern Med 2001;161:1814-1824.

11. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364.

12. Pasquali R, Casimitri F, Melchionda N, et al. Effects of chronic administration of ephedrine during very-low calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. Clin Sci 1992;82:85-92.

13. Lorello C, Goldfield GS, Doucer E. Methylphenidate hydrochloride increases energy expenditure in healthy adults. Obesity 2008;16:470-472.

14. Jones JR, Caul WF, Hill JO. The effects of amphetamine on body weight and energy expenditure. Physiol Behav 1992;51:607-611.

15. Lang SS, Danforth E Jr, Lien EL. Anoretic drugs which stimulate termogénesis. Life Sci 1983;33:1269-1275.

16. Jaworska I, Budziszewska B, Lason W. The effect of repeated amphetamine administration on the proopiomelanocortin mRNA level in the rat pituitary. Drug Alcohol Depend 1994;36:123-127.

17. Menyhert J, Wirtmann G, Lechan RM, et al. Cocaine and amphetamine-regulated transcript (CART) is colocalized with the orexigenic neuropeptide Y and agouti-related protein and absent from the anorexigenic alpha-melanocyte- stimulating hormone neurons in the infundibular nucleus of the human hypothalamus. Endocrinology 2007;148:4276-4281.

18. Braga MF, Aroniadou-Andrejaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kaniate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther 2009;330:558- 566.

19. Khazaal Y, Zullino DF. Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol 2007;63:891-892.

20. McElroy SL, Arnold ML, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trail. Am J Psychiatr 2003;160:255-261.

21. Khazaal Y, Zullino DF. Topiramate in the treatment of compulsive sexual behaviour: case report. BMC Psychiatry 2006; 6:22.

22. Turenius CI, Htut MM, Prodon DA, et al. GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res 2009;1262:16-24.

23. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4:275-282.

24. Erondu N, Wadden T, Grantz I, et al. Effect of NPY5R antagonism MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity 2007;15:895-905.

25. Husum H, Van Kammen D, Terneer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line depressed rats and upregulates NPY, galanin and CRH-LI in the hyppothalamus: implications for mood-stabilizing and weight loss-induced effects. Neuropsychopharmacology 2003;28:1292-1299.

26. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308.

27. Allison DB, Gadde KM, Garvey WT. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2011;20:330-342.

28. Gadde KM, Allison DB, Ryan DH, et al. Effects of lowdose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a radomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341- 1352.

29. World Health Organization. Energy and protein requirements. In: Report a Joint FAO/WHO/UNU Expert Consultation. Geneva: World Health Organization, 1985.

30. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-1095.

31. Kim B. Thyroid hormone as a determination of energy expenditure and the basal metabolic rate. Thyroid 2008;18:141-144.

32. Bushnell PJ. Diferential effects of amphetamine and related compunds on locomotor activity and metabolic rate in mice. Pharmacol Biochem Behav 1986;25:161-170.

33. Picard F, Deshaies Y, Lalonde J, et al. Topiramato reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656-663.

34. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. J Obes Relat Metab Disord 2002;26:344-353.